Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…Abstract Number: 598 • 2017 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration
Background/Purpose: To evaluate the efficacy of ustekinumab (UST) by prior treatment exposure and disease duration in adult PsA patients (pts) in the Phase 3 trials…Abstract Number: 599 • 2017 ACR/ARHP Annual Meeting
Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24
Background/Purpose: The GO-VIBRANT study was designed to evaluate the safety and efficacy of intravenous (IV) golimumab (GLM) in adult patients (pts) with active PsA (biologic-naïve).…Abstract Number: 632 • 2017 ACR/ARHP Annual Meeting
Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?
Background/Purpose: The efficacy of Golimumab (GLM) treatment in psoriatic arthritis (PsA) patients has been widely documented. The aim of this study was to analyze the…Abstract Number: 2514 • 2016 ACR/ARHP Annual Meeting
Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? an Analysis from Rhumadata® over 12 Years
Background/Purpose: In rheumatoid arthritis, it has been shown that anti-TNF therapy (TNFi) in combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD), often methotrexate (MTX),…Abstract Number: 2767 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component
Background/Purpose: Minimal disease activity (MDA) is now considered an attainable target in psoriatic arthritis (PsA) reflecting a desired state of comprehensive disease control. MDA is…Abstract Number: 2146 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Background/Purpose: There remains an unmet need for additional treatment options for patients (pts) with psoriatic arthritis (PsA) who have had an inadequate response to or…Abstract Number: 333 • 2013 ACR/ARHP Annual Meeting
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with progressive joint damage and disability. In the last 15 years, tumour necrosis factor inhibitors…Abstract Number: 1357 • 2012 ACR/ARHP Annual Meeting
Psoriatic Arthritis and Biologic Therapy: Treatment Response, Drug Survival and Outcome After Switching
Background/Purpose: Data on longer term efficacy and tolerance of biologic therapies in psoriatic arthritis (PsA) are emerging. Persistence with the first TNF inhibitor (TNFi) at…